Sodium glucose co-transporter-2 inhibitor, Empagliflozin, is associated with significant reduction in weight, body mass index, fasting glucose, and A1c levels in Type 2 diabetic patients with established coronary heart disease: the SUPER GATE study.

Satilmis BilginOzge KurtkulagiTuba Taslamacioglu DumanBurcin Meryem Atak TelGizem KahveciMurat KiranEray ErgeGulali Aktas

Published in: Irish journal of medical science (2021)

We suggest that empagliflozin treatment may improve anthropometric measures, metabolic parameters, and blood pressure and does not cause deterioration in kidney functions in type 2 diabetic patients with established coronary heart disease.

Keyphrases

body mass index
blood pressure
blood glucose
weight gain
physical activity
body composition
weight loss
insulin resistance
hypertensive patients
type diabetes
adipose tissue
smoking cessation
body weight
replacement therapy